Fig. 6: KRAS affects the TME by modulating amino acid metabolism. | Cell Death & Disease

Fig. 6: KRAS affects the TME by modulating amino acid metabolism.

From: Oncogenic KRAS mutations drive immune suppression through immune-related regulatory network and metabolic reprogramming

Fig. 6: KRAS affects the TME by modulating amino acid metabolism.

Mutant KRAS upregulates SLC25A22 expression, promotes ERK/ETS2 signaling, and activates CXCL1/CXCR2 pathway to recruit MDSC. KRAS regulates the SLC7A5/mTORC1 pathway to promote tumor proliferation. KRAS/LKB1 co-mutations increased glutamate levels and glutaminase expression. Glutamate abundance in LKB1-deficient TME promoted T cell activation in response to anti-PD-1.

Back to article page